Biological E Covid Vaccine
-
{
- All
- News
- Videos
-
Biological E, Bharat Biotech Have 250 Million Covid Vaccine Stockpile: Report
Two major vaccine makers from Hyderabad, Biological E Ltd and Bharat Biotech, together are holding about 250 million doses of COVID-19 vaccines ready to dispatch as and when orders are received.
-
100 Million Corbevax Doses Supplied To Centre, Says Biological E
Biological E. Ltd (BE) on Thursday said it has delivered 10 crore (100 million) doses of its COVID-19 vaccine, Corbevax, to the Centre so far.
-
Corbevax Approved As Booster Dose For Adults Vaccinated With Covaxin, Covishield
The government on Wednesday approved Biological E's Corbevax as a precaution dose for those above 18 years fully vaccinated with either Covishield or Covaxin.
-
Corbevax Cleared As Covid Booster Shot For Those 18 And Above
Biological E's COVID-19 vaccine Corbevax has been cleared for booster shot for those 18 and above.
-
Biological E's Corbevax Is Second Covid Vaccine For Children In India
A second COVID-19 vaccine for children has received emergency use authorisation in India. Biological E Ltd's Corbevax has got EUA for children and teens between 12 and 18 years, the vaccine-maker said in a statement today.
-
Biological E Aims To Produce 100 Million Doses Of Corbevax Every Month From Feb 2022
Biological E. Limited plans to complete production at a rate of 75 million doses of its COVID-19 vaccine Corbevax per month, anticipating over 100 million doses per month from February 2022.
-
Texas-India Vaccine Diplomacy Announces Covid Vaccine For $1.5 Per Dose
The Texas-India vaccine diplomacy, a collaboration for shared global health between Indian pharmaceutical company Biological E and the Texas Children''s Hospital and Baylor College of Medicine, has led to the development of a cost-efficient vaccine
-
India's Biological E, US Finalise $50 Million Covid Vaccine Deal: Report
The United States and India's Biological E. Ltd said on Monday they had finalised a financing arrangement for $50 million to expand the vaccine maker's capacity to produce COVID-19 shots.
-
Hyderabad's Biological E Expects To Rollout Corbevax Covid Vaccine By November-End
Biological E. Limited (BE) is expecting its COVID-19 vaccine Corbevax to be rolled out by the end of November even as the city-based firm is getting ready with 100 million doses for the launch, Mahima Datla, Managing Director, BE said on Monday.
-
US To Finance India's Biological E In $50 Million Covid Vaccine Deal
The United States and India's Biological E. Ltd said on Monday they had finalised a financing arrangement for $50 million to expand the vaccine maker's capacity to produce COVID-19 shots.
-
Biological E Seeks Regulator's Nod For Phase-3 Trial Of Booster Dose
Biological E has sought permission from India's drug regulator to conduct the phase-3 clinical trial for its COVID-19 vaccine Corbevax as a single booster dose for those who have been fully vaccinated with Covishield or Covaxin.
-
Biological E Gets Nod For Further Trials Of Its Covid Vaccine On Children
Biological E has received approval for conducting phase II/III human clinical trial of COVID-19 vaccine candidate Corbevax on children above five years and adolescents, the Department of Biotechnology said today.
-
Made-In-India Biological E Vaccine May Be 90% Effective, "Game-Changer"
Biological E's made-in-India vaccine is expected to have 90 per cent effectiveness against Covid and will likely be a gamechanger in the fight against the pandemic, says a top doctor on a government advisory panel.
-
Hyderabad Drugmaker To Make Canada Firm's mRNA Covid Vaccine In India
Hyderabad-based Biological E said on Tuesday it has entered into a licensing agreement with Providence Therapeutics Holdings to manufacture the Canadian company's mRNA COVID-19 vaccine in India.
-
Centre Looking Into Securing Part Of J&J Vaccine Shots For India: Report
J&J's COVID-19 vaccine, to be manufactured in India by Biological E, will have to be handed over entirely to the US pharma giant as agreed but the government is looking at the possibility of securing a part of this production, sources said.
-
Biological E, Bharat Biotech Have 250 Million Covid Vaccine Stockpile: Report
Two major vaccine makers from Hyderabad, Biological E Ltd and Bharat Biotech, together are holding about 250 million doses of COVID-19 vaccines ready to dispatch as and when orders are received.
-
100 Million Corbevax Doses Supplied To Centre, Says Biological E
Biological E. Ltd (BE) on Thursday said it has delivered 10 crore (100 million) doses of its COVID-19 vaccine, Corbevax, to the Centre so far.
-
Corbevax Approved As Booster Dose For Adults Vaccinated With Covaxin, Covishield
The government on Wednesday approved Biological E's Corbevax as a precaution dose for those above 18 years fully vaccinated with either Covishield or Covaxin.
-
Corbevax Cleared As Covid Booster Shot For Those 18 And Above
Biological E's COVID-19 vaccine Corbevax has been cleared for booster shot for those 18 and above.
-
Biological E's Corbevax Is Second Covid Vaccine For Children In India
A second COVID-19 vaccine for children has received emergency use authorisation in India. Biological E Ltd's Corbevax has got EUA for children and teens between 12 and 18 years, the vaccine-maker said in a statement today.
-
Biological E Aims To Produce 100 Million Doses Of Corbevax Every Month From Feb 2022
Biological E. Limited plans to complete production at a rate of 75 million doses of its COVID-19 vaccine Corbevax per month, anticipating over 100 million doses per month from February 2022.
-
Texas-India Vaccine Diplomacy Announces Covid Vaccine For $1.5 Per Dose
The Texas-India vaccine diplomacy, a collaboration for shared global health between Indian pharmaceutical company Biological E and the Texas Children''s Hospital and Baylor College of Medicine, has led to the development of a cost-efficient vaccine
-
India's Biological E, US Finalise $50 Million Covid Vaccine Deal: Report
The United States and India's Biological E. Ltd said on Monday they had finalised a financing arrangement for $50 million to expand the vaccine maker's capacity to produce COVID-19 shots.
-
Hyderabad's Biological E Expects To Rollout Corbevax Covid Vaccine By November-End
Biological E. Limited (BE) is expecting its COVID-19 vaccine Corbevax to be rolled out by the end of November even as the city-based firm is getting ready with 100 million doses for the launch, Mahima Datla, Managing Director, BE said on Monday.
-
US To Finance India's Biological E In $50 Million Covid Vaccine Deal
The United States and India's Biological E. Ltd said on Monday they had finalised a financing arrangement for $50 million to expand the vaccine maker's capacity to produce COVID-19 shots.
-
Biological E Seeks Regulator's Nod For Phase-3 Trial Of Booster Dose
Biological E has sought permission from India's drug regulator to conduct the phase-3 clinical trial for its COVID-19 vaccine Corbevax as a single booster dose for those who have been fully vaccinated with Covishield or Covaxin.
-
Biological E Gets Nod For Further Trials Of Its Covid Vaccine On Children
Biological E has received approval for conducting phase II/III human clinical trial of COVID-19 vaccine candidate Corbevax on children above five years and adolescents, the Department of Biotechnology said today.
-
Made-In-India Biological E Vaccine May Be 90% Effective, "Game-Changer"
Biological E's made-in-India vaccine is expected to have 90 per cent effectiveness against Covid and will likely be a gamechanger in the fight against the pandemic, says a top doctor on a government advisory panel.
-
Hyderabad Drugmaker To Make Canada Firm's mRNA Covid Vaccine In India
Hyderabad-based Biological E said on Tuesday it has entered into a licensing agreement with Providence Therapeutics Holdings to manufacture the Canadian company's mRNA COVID-19 vaccine in India.
-
Centre Looking Into Securing Part Of J&J Vaccine Shots For India: Report
J&J's COVID-19 vaccine, to be manufactured in India by Biological E, will have to be handed over entirely to the US pharma giant as agreed but the government is looking at the possibility of securing a part of this production, sources said.
